Abstract: A transistor-type sensor capable of detecting a compound having an amino group has a simple structure and also is expected to be effective in antioxidation action and prevention of dementia, etc. The transistor-type sensor includes a detection electrode for capturing a compound having an amino group for detection, and a transistor having a gate electrode connected with the detection electrode. The detection electrode has a cucurbituril structure-containing compound immobilized on the surface thereof.

Abstract: This present disclosure relates to the use of syncytiotrophoblast-derived microvesicles for diagnosing and/or monitoring a subject with preeclampsia. Accordingly, this disclosure provides for methods for isolating, purifying, and/or detecting syncytiotrophoblast-derived microvesicles from a biological fluid of a pregnant subject. The present disclosure also provides kits for diagnosing a subject with preeclampsia, where the kit contains reagents useful for isolating, purifying, and/or identifying the syncytiotrophoblast-derived microvesicles in a biological sample and for detecting one or more biomarkers present on the surface of or within the syncytiotrophoblast-derived microvesicles.

Abstract: Carbon materials formed using various templates of precursor materials are described in addition to method and process for producing the same.

Abstract: A system that provides the ability to integrate both diagnostic tissue detection and therapeutic tissue treatment functionality in an implantable medical device (IMD), such as a graft or stent. The system comprises: an IMD having a pair of electrodes configured to contact biological tissue at an implant location; an impedance sensor configured to detect data indicative of a complex impedance of the biological tissue at the electrodes for a plurality of frequencies; and an analysis device configured to determine one or more cell types in the biological tissue using information indicative of variation in phase and magnitude of the complex impedance across the plurality of frequencies. The system may include a signal generator for applying a treatment signal to the same electrodes.

Abstract: Combination therapies for the treatment of cancers are provided. In some embodiments, a flagellin derivative such as CBLB502 is administered in combination with an immune checkpoint therapy (e.g., an anti-PD 1 antibody and an anti-CTLA4 antibody) to treat a cancer in a mammalian subject. In some embodiments, the combination therapy is administered intratumorally or peritumorally.

Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

Abstract: The strigolactone receptor inhibitor for plants contains at least one kind of triazole urea compounds represented by the following formula (I) as an active ingredient. It can be applicable to an agricultural composition; a method for using the agricultural composition as, for example, a branching enhancer for plants; a germination inhibitor for Striga seeds, the germination inhibitor containing the triazole urea compound; and a novel triazole urea compound that is useful as a strigolactone receptor inhibitor for plants. In the formula, A represents a group represented by (A-1) or (A-2). R1 and R2 represent a hydrogen atom and so forth. R3 and R4 represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, or an aryl group having 6 to 20 carbon atoms and so forth. R3 and R4 may form a ring together.

Abstract: The present disclosure provides methods of treating cancer in a patient comprising administering a combination of a low dose radiotherapy and an immune checkpoint inhibitor therapy. The patient may be further administered a cell therapy, such as chimeric antigen receptor T-cell therapy or chimeric antigen receptor NK-cell therapy. The low dose radiation modulates the tumor microenvironment of solid tumors to allow better efficacy, activation, and infiltration of the anti-tumor effector immune cells.

Abstract: The present invention provides Factor IX fusion proteins with higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein.

Abstract: The present invention relates to monolithic bodies, uses thereof and processes for the preparation thereof. Certain embodiments of the present invention relate to the use of a monolithic body in the preparation of a radioactive substance, for example a radiopharmaceutical, as part of a microfluidic flow system and a process for the preparation of such a monolithic body.

Abstract: Various embodiments of the present technology enable growth of a-axis oriented barium titanate (BTO) films by inserting a relaxed strain control layer having a larger lattice constant than the c-axis of BTO and a similar thermal expansion mismatch. As a result, in-plane tensile stress causes BTO to grow with its ferroelectric polarization in-plane. Some embodiments allow for BTO films to immediately be grown on silicon with a-axis orientation, and without the need to create thick layers for relaxation. Using various embodiments of the present technology, the BTO can be grown in-plane with minimal dislocation density that is confined to the interface region.

Abstract: Embodiments of the present invention provide a computer-implemented method of determining a parameter indicative of dark adaptation of an eye, comprising receiving threshold data from a dark adaptometer indicative of a perception threshold of the eye, fitting first and second models to the threshold data, wherein the first model is associated with a first dark adaptation mechanism and the second model is associated with the first dark adaption mechanism and a second dark adaptation mechanism, determining a confidence associated with the fitting of each of the first and second models to the received threshold data, iteratively repeating the steps of receiving the threshold data and fitting the first and second models in dependence on the determined confidence, and outputting an indication of one or more parameters indicative of dark adaptation of an eye associated with one or both of the first and second models.

Abstract: Systems and methods for quantum clock synchronization are provided. Various embodiments can use time-energy and polarization entangled photons to securely extract the absolute time difference between two remote clocks. In some embodiments, two parties can each have a source of entangled photons. Each party can detect one member of the pair locally and time stamp the detection time, while the other photon gets sent over a common channel (single optical mode) to the other party where the transmitted photon is detected and time stamped. The time stamp values can be shared over an open authenticated channel and each receiver can run a cross-correlation of the detection times. The authenticity and non-spoofability of the timing signal are ensured if each party does not just perform a simple time of arrival measurement but also incorporate polarization measurements whose joint values constitute a Bell test.

Abstract: Materials that exhibit stress-induced porosity, and methods of making and using the same, are described.

Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

Abstract: Various implementations include a Human Thermoregulation Simulator (HTRS) that simulates the natural and primary thermoregulatory functions of a patient that are relevant during therapeutic hypothermia procedures. For example, in various implementations, a HTRS includes a core container configured to be at least partially filled with water, and the core container includes a heat generator configured to heat the water inside the core container. A middle container is disposed concentrically around the core container, and the middle container includes a foam layer configured to be saturated by water. An outer container is disposed concentrically around the middle container, and the outer container includes a network of tubing disposed on at least a portion of an inner surface of the outer container. The HTRS also includes a pump configured to circulate water from the core container through the network of tubing.

Abstract: Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target B7-H3. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an B7-H3-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of B7-H3.

Abstract: A readout integrated circuit (IC) architecture for a tunnelling magnetoresistive (TMR) sensor which uses common mode feedback to achieve a performance level suitable for accurate detection of biomagnetic signals. The architecture uses a three-operational amplifier configuration with chopper stabilization. The architecture may form part of a fully integrated biomagnetic sensor electronics package that includes an array of TMR sensors together with modules for signal amplification and conditioning, data conversion and communication.

Abstract: Methods and systems for predicting surface failure of a surface, for example a method comprising the steps of: obtaining a group of measured datasets, each including: a measurement value of at least a first type for each of a plurality of grid elements, each grid element associated with a location on the surface; and a time value, such that the group of datasets includes datasets associated with a plurality of unique time values, identifying an interface set of grid elements for each measured dataset, each interface set comprising grid elements of the associated measured dataset meeting a connection threshold according to a connection rule in dependence on the measurement values of the grid elements, determining a risk of surface failure in accordance with identification of a pattern of grid elements of the interface set which has a persistent location with respect to the surface of interface sets over a plurality of measured datasets.

Abstract: Provided is a refrigerant distributor including: a first space forming portion having a first refrigerant port and a second refrigerant port; and a second space forming portion, which extends laterally from a lower part of the first space forming portion, and has a plurality of heat transfer pipe connecting portions. A gas-liquid refrigerant mixture flows into the first space forming portion through the first refrigerant port. Heat transfer pipes are connected at positions of the plurality of heat transfer pipe connecting portions in the second space forming portion.